Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opportunities to Optimize Cancer Policies Panel Discussion

Jul

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opportunities to Optimize Cancer Policies Panel Discussion

New Research Offers Reassurance About Localized Prostate Cancer Prognosis

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

Surgery vs Ablation in Small Hepatocellular Carcinoma

Chemoimmunotherapy for Advanced BTC 3-Year Overall Survival Update From the TOPAZ Trial

Optimizing the CAR to the Disease in B-Cell Malignancies